Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Double-blind Randomized Phase III Study of 300 mg Versus 150 mg Erlotinib in Current Smokers With Locally Advanced or Metastatic NSCLC in Second-line Setting After Failure on Chemotherapy (CURRENTS)

NCT01183858 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01183858
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01183858 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Double-blind Randomized Phase III Study of 300 mg Versus 150 mg Erlotinib in Current Smokers With Locally Advanced or Metastatic NSCLC in Second-line Setting After Failure on Chemotherapy (CURRENTS)
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2010
Completion date
February 28, 2014
Enrollment
315 (actual)
Sites
63

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer